Figure 1. Research Method Flow Chart 11
Figure 2. Bottom-up Approach and Top-down Approach for Market Estimation 14
Figure 3. Asia Pacific Market Forecast in Optimistic, Conservative and Balanced Perspectives, 2020-2027 16
Figure 4. Asia Pacific Multiple Sclerosis Drugs Market, 2017-2027, $ mn 19
Figure 5. Impact of COVID-19 on Business 22
Figure 6. Primary Drivers and Impact Factors of Asia Pacific Multiple Sclerosis Drugs Market 24
Figure 7. Worldwide Geriatric Population (60 years and above) by Regions, 2015 & 2030, million 27
Figure 8. World Population 65 and Over, % of Total Population, 1950-2060 27
Figure 9. Primary Restraints and Impact Factors of Asia Pacific Multiple Sclerosis Drugs Market 29
Figure 10. Investment Opportunity Analysis 34
Figure 11. Porter’s Fiver Forces Analysis of Asia Pacific Multiple Sclerosis Drugs Market 37
Figure 12. Breakdown of Asia Pacific Multiple Sclerosis Drugs Market by Drug Type, 2020-2027, % of Revenue 41
Figure 13. Contribution to Asia Pacific 2021-2027 Cumulative Revenue by Drug Type, Value ($ mn) and Share (%) 42
Figure 14. Asia Pacific Multiple Sclerosis Drugs Market: Immunomodulators, 2017-2027, $ mn 43
Figure 15. Asia Pacific Multiple Sclerosis Drugs Market: Immunosuppressants, 2017-2027, $ mn 45
Figure 16. Breakdown of Asia Pacific Multiple Sclerosis Drugs Market by Drug Class, 2020-2027, % of Revenue 48
Figure 17. Contribution to Asia Pacific 2021-2027 Cumulative Revenue by Drug Class, Value ($ mn) and Share (%) 48
Figure 18. Asia Pacific Multiple Sclerosis Drugs Market: Monoclonal Antibodies, 2017-2027, $ mn 49
Figure 19. Asia Pacific Multiple Sclerosis Drugs Market: Interferon Beta, 2017-2027, $ mn 50
Figure 20. Asia Pacific Multiple Sclerosis Drugs Market: Sphingosine 1 Phosphate Receptor Modulators, 2017-2027, $ mn 51
Figure 21. Asia Pacific Multiple Sclerosis Drugs Market: Mixed Polymers, 2017-2027, $ mn 52
Figure 22. Asia Pacific Multiple Sclerosis Drugs Market: NF-?B Inhibitor, 2017-2027, $ mn 53
Figure 23. Asia Pacific Multiple Sclerosis Drugs Market: Pyrimidine Synthesis Inhibitor, 2017-2027, $ mn 54
Figure 24. Asia Pacific Multiple Sclerosis Drugs Market: Corticosteroids, 2017-2027, $ mn 55
Figure 25. Asia Pacific Multiple Sclerosis Drugs Market: Adrenocorticotropic Hormone, 2017-2027, $ mn 56
Figure 26. Asia Pacific Multiple Sclerosis Drugs Market: Other Drug Classes, 2017-2027, $ mn 57
Figure 27. Breakdown of Asia Pacific Multiple Sclerosis Drugs Market by Drug Category, 2020-2027, % of Revenue 58
Figure 28. Contribution to Asia Pacific 2021-2027 Cumulative Revenue by Drug Category, Value ($ mn) and Share (%) 59
Figure 29. Asia Pacific Multiple Sclerosis Drugs Market: Large-molecule Drugs, 2017-2027, $ mn 60
Figure 30. Asia Pacific Multiple Sclerosis Drugs Market: Small-molecule Drugs, 2017-2027, $ mn 61
Figure 31. Breakdown of Asia Pacific Multiple Sclerosis Drugs Market by Route of Administration, 2020-2027, % of Revenue 62
Figure 32. Contribution to Asia Pacific 2021-2027 Cumulative Revenue by Route of Administration, Value ($ mn) and Share (%) 63
Figure 33. Asia Pacific Multiple Sclerosis Drugs Market: Oral Administration, 2017-2027, $ mn 64
Figure 34. Asia Pacific Multiple Sclerosis Drugs Market: Parenteral Administration, 2017-2027, $ mn 65
Figure 35. Breakdown of Asia Pacific Multiple Sclerosis Drugs Market by MS Type, 2020-2027, % of Revenue 66
Figure 36. Contribution to Asia Pacific 2021-2027 Cumulative Revenue by MS Type, Value ($ mn) and Share (%) 67
Figure 37. Asia Pacific Multiple Sclerosis Drugs Market: Relapsing-remitting MS (RRMS), 2017-2027, $ mn 68
Figure 38. Asia Pacific Multiple Sclerosis Drugs Market: Primary-progressive MS (PPMS), 2017-2027, $ mn 69
Figure 39. Asia Pacific Multiple Sclerosis Drugs Market: Secondary-progressive MS (SPMS), 2017-2027, $ mn 70
Figure 40. Asia Pacific Multiple Sclerosis Drugs Market: Progressive-relapsing MS (PRMS), 2017-2027, $ mn 71
Figure 41. Breakdown of Asia Pacific Multiple Sclerosis Drugs Market by Distribution Channel, 2020-2027, % of Revenue 72
Figure 42. Contribution to Asia Pacific 2021-2027 Cumulative Revenue by Distribution Channel, Value ($ mn) and Share (%) 73
Figure 43. Asia Pacific Multiple Sclerosis Drugs Market: Hospital Pharmacies, 2017-2027, $ mn 74
Figure 44. Asia Pacific Multiple Sclerosis Drugs Market: Retail Pharmacies, 2017-2027, $ mn 75
Figure 45. Asia Pacific Multiple Sclerosis Drugs Market: Online Pharmacies, 2017-2027, $ mn 76
Figure 46. Breakdown of APAC Multiple Sclerosis Drugs Market by Country, 2020 and 2027, % of Revenue 78
Figure 47. Contribution to APAC 2021-2027 Cumulative Revenue by Country, Value ($ mn) and Share (%) 79
Figure 48. Multiple Sclerosis Drugs Market in China, 2017-2027, $ mn 80
Figure 49. Multiple Sclerosis Drugs Market in Japan, 2017-2027, $ mn 83
Figure 50. Multiple Sclerosis Drugs Market in India, 2017-2027, $ mn 85
Figure 51. Multiple Sclerosis Drugs Market in Australia, 2017-2027, $ mn 87
Figure 52. Multiple Sclerosis Drugs Market in South Korea, 2017-2027, $ mn 89
Figure 53. Multiple Sclerosis Drugs Market in Rest of APAC, 2017-2027, $ mn 91
Figure 54. Growth Stage of Asia Pacific Multiple Sclerosis Drugs Industry over the Forecast Period 93
Asia Pacific multiple sclerosis drugs market will grow by 6.5% annually with a total addressable market cap of $33.56 billion over 2120-2027 owing to the growing prevalence of multiple sclerosis (MS), the rise in funding for multiple sclerosis research, and increasing approvals of novel MS drugs. Highlighted with 35 tables and 54 figures, this 110-page report “Asia Pacific Multiple Sclerosis Drugs Market 2020-2027 by Drug Type (Immunomodulators, Immunosuppressants), Drug Class, Drug Category (Large-molecule, Small-molecule), Route of Administration (Oral, Parenteral), MS Type (RRMS, PPMS, SPMS, PRMS), Distribution Channel, and Country: Trend Outlook and Growth Opportunity” is based on a comprehensive research of the entire Asia Pacific multiple sclerosis drugs market and all its sub-segments through extensively detailed classifications. Profound analysis and assessment are generated from premium primary and secondary information sources with inputs derived from industry professionals across the value chain. The report is based on studies on 2017-2019 and provides estimate for 2020 and forecast from 2021 till 2027 with 2019 as the base year. (Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.) In-depth qualitative analyses include identification and investigation of the following aspects: • Market Structure • Growth Drivers • Restraints and Challenges • Emerging Product Trends & Market Opportunities • Porter’s Fiver Forces The trend and outlook of Asia Pacific market is forecast in optimistic, balanced, and conservative view by taking into account of COVID-19. The balanced (most likely) projection is used to quantify Asia Pacific multiple sclerosis drugs market in every aspect of the classification from perspectives of Drug Type, Drug Class, Drug Category, Route of Administration, MS Type, Distribution Channel, and Country. Based on Drug Type, the Asia Pacific market is segmented into the following sub-markets with annual revenue ($ mn) for 2017-2027 included in each section. • Immunomodulators o Copaxone o Avonex/Plegridy o Gilneya o Tysabri o Betaseron/Extavia o Tecifidera o Rebif o Ampyra o Other Immunomodulators • Immunosuppressants o Aubagio o Lemtrada o Ocrelizumab o Zinbryta o Other Immunosuppressants Based on Drug Class, the Asia Pacific market is segmented into the following sub-markets with annual revenue ($ mn) for 2017-2027 included in each section. • Monoclonal Antibodies • Interferon Beta • Sphingosine 1 Phosphate Receptor Modulators • Mixed Polymers • NF-?B Inhibitor • Pyrimidine Synthesis Inhibitor • Corticosteroids • Adrenocorticotropic Hormone • Other Drug Classes Based on Drug Category, the Asia Pacific market is segmented into the following sub-markets with annual revenue ($ mn) for 2017-2027 included in each section. • Large-molecule Drugs • Small-molecule Drugs Based on Route of Administration, the Asia Pacific market is segmented into the following sub-markets with annual revenue ($ mn) for 2017-2027 included in each section. • Oral Administration • Parenteral Administration Based on MS Type, the Asia Pacific market is segmented into the following sub-markets with annual revenue ($ mn) for 2017-2027 included in each section. • Relapsing-remitting MS (RRMS) • Primary-progressive MS (PPMS) • Secondary-progressive MS (SPMS) • Progressive-relapsing MS (PRMS) Based on Distribution Channel, the Asia Pacific market is segmented into the following sub-markets with annual revenue ($ mn) for 2017-2027 included in each section. • Hospital Pharmacies • Retail Pharmacies • Online Pharmacies Geographically, the following national/local markets are fully investigated: • Japan • China • South Korea • Australia • India • Rest of APAC (further segmented into Malaysia, Singapore, Indonesia, Thailand, New Zealand, Vietnam, Taiwan, and Philippines) For each key country, detailed analysis and data for annual revenue ($ mn) are available for 2017-2027. The breakdown of key national markets by Drug Type, Route of Administration, and Distribution Channel over the forecast years are also included. The report also covers current competitive scenario and the predicted trend; and profiles key vendors including market leaders and important emerging players. Key Players (this may not be a complete list and extra companies can be added upon request): Abbvie, Inc. Acorda Therapeutics Inc. Bayer AG Biogen Inc. Bristol-Myers Squibb Company F. Hoffmann-La Roche Ltd. Merck KgaA Mylan NV Novartis AG Pfizer Inc. Sanofi SA Teva Pharmaceutical Industries Ltd. (Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)
Read More